Patients with NSCLC harboring EGFR activating mutation showed a good response to the first- (gefitinib, erlotinib) and second-generation (afatinib) of EGFR-tyrosine kinase inhibitors (TKIs), but they developed acquired resistance in about 9–13 months (6). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.